Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05271292 · ClinicalTrials.gov registry record · Phase 1
Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.
A Phase 1 study of Small-cell Lung Cancer and Advanced Solid Malignant Tumor, sponsored by Chipscreen Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 11
- Study locations
NCT05271292 is a Phase 1 study of Small-cell Lung Cancer and Advanced Solid Malignant Tumor that is actively recruiting participants, run by Chipscreen Biosciences. The registered enrollment target is 36 participants, below the 232-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (84% lower). The trial reports 11 study locations across 10 states.
The verdict
NCT05271292, a Phase 1 study of Small-cell Lung Cancer and Advanced Solid Malignant Tumor, is actively recruiting participants, sponsored by Chipscreen Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages: Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods) Phase 2: recommended Phase 2 dose (RP2D) of chiauranib will be given to all patients enrolled in this phase once daily for 28-day cycles continuously with no interruption between cycles.
Conditions Studied
Interventions
- DRUG Chiauranib
Study Locations (11)
California
- California Cancer Associates-Encintas - Encinitas
- Providence/St. Joe Cancer Institute/Crosson Cancer Institute - Fullerton
Georgia
- Winship Cancer Institute of Emory University - Atlanta
Massachusetts
- Dana Farber Cancer Institue - Boston
Michigan
- Karmanos Cancer Institute - Detroit
Nevada
- Comprehensive Cancer Centers of Nevada - Las Vegas
Ohio
- Gabrail Cancer Center Research - Canton
Oklahoma
- OU Health - Oklahoma City
Tennessee
- Sarah Cannon Research Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-08-26 |
| Est. Completion | 2025-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05271292
The ClinicalTrials.gov registry entry for NCT05271292 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 232-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (84% lower). The listed sponsor is Chipscreen Biosciences, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Chiauranib is the first listed.
NCT05271292 reports 11 study locations spanning 10 distinct geographic areas - top geographies include California, Georgia, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05271292 about?
NCT05271292 is a clinical study titled "Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.". This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages: Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods) Phase 2: recommended Phase 2 dose (RP2D) of chiauranib will be given to all patients enrolled in this phase once daily for 28-day cycle...
What is the current status of trial NCT05271292?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2022-08-26. Estimated completion is 2025-05.
What conditions does trial NCT05271292 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer, Advanced Solid Malignant Tumor.
What interventions are being tested in trial NCT05271292?
The interventions under investigation include: Chiauranib (DRUG).
Who is sponsoring clinical trial NCT05271292?
This trial is sponsored by Chipscreen Biosciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05271292 being conducted?
This trial has 11 study locations across California, Georgia, Massachusetts, Michigan, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
RECRUITING · Phase 1
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.